Pirofsky B, Nolte M T, Bardana E J
Transplantation. 1975 Nov;20(5):357-61. doi: 10.1097/00007890-197511000-00001.
Immunological function was evaluated in 9 patients who received oxisuran at a dose range of 5-90 mg/kg, for periods of 5-40 weeks. Bone marrow cytotoxicity and lymphopenia did not occur. Established humoral immunological reactions were unaffected by oxisuran. Only 6 of 19 previously positive skin tests reverted to negative. Primary cellular immune reactivity was markedly suppressed. Allogenic skin graft survival was prolonged to a mean of 30.7 days and only 2 of 9 patients were successfully sensitized to dinitrochlorobenzene and Keyhole limpet hemocyanin, respectively. Both IgG and IgM responses to primary typhoid immunization were inhibited. In vitro peripheral blood lymphocyte activity in phytohemagglutinin and mixed lymphocyte culture tests remained normal. These data suggest that oxisuran interferes with the afferent limb of the immune system and may thereby be clinically useful in human transplantation.
对9名接受剂量范围为5 - 90mg/kg奥昔舒仑治疗5 - 40周的患者进行了免疫功能评估。未出现骨髓细胞毒性和淋巴细胞减少。已建立的体液免疫反应不受奥昔舒仑影响。19项先前呈阳性的皮肤试验中只有6项转为阴性。原发性细胞免疫反应明显受到抑制。同种异体皮肤移植存活期延长至平均30.7天，9名患者中只有2名分别成功对二硝基氯苯和钥孔戚血蓝蛋白致敏。对伤寒初次免疫的IgG和IgM反应均受到抑制。在体外植物血凝素和混合淋巴细胞培养试验中，外周血淋巴细胞活性保持正常。这些数据表明，奥昔舒仑干扰免疫系统的传入支，因此在人体移植中可能具有临床应用价值。
